Investment analysts at StockNews.com assumed coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Idera Pharmaceuticals Price Performance
IDRA stock opened at $0.36 on Monday. The company has a market cap of $19.10 million, a P/E ratio of -1.13 and a beta of 1.50. Idera Pharmaceuticals has a 1 year low of $0.30 and a 1 year high of $0.95. The stock’s fifty day moving average price is $0.40 and its 200-day moving average price is $0.45.
Idera Pharmaceuticals shares are scheduled to split on Friday, November 25th. The 2-1 split was announced on Friday, November 25th. The newly minted shares will be issued to shareholders after the closing bell on Friday, November 25th.
Hedge Funds Weigh In On Idera Pharmaceuticals
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer.
- Get a free copy of the StockNews.com research report on Idera Pharmaceuticals (IDRA)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.